EDGE MEDICAL-B (02675) saw its shares rise more than 6% during the trading session. At the time of writing, the stock was up 6.28%, trading at HK$57.5, with a turnover of HK$22.9121 million. The increase follows news that the company's fully self-developed "multi-port + single-port + remote" integrated surgical robot platform, described as the world's first and currently only one of its kind, has received market approval from the National Medical Products Administration (NMPA). This approval signifies a critical milestone for EDGE MEDICAL-B's "three-in-one" minimally invasive surgical innovation solution, marking its transition from technological exploration and product development to regulatory endorsement. It also represents a major breakthrough in platform innovation, system integration, and clinical application expansion for China's high-end surgical robotics sector. As the first company in China and the second globally to simultaneously obtain regulatory approval for multi-port, single-port laparoscopic, and natural orifice surgical robots, EDGE MEDICAL-B has established a comprehensive product portfolio. With the formal NMPA approval of the "three-in-one" platform, the company plans to further advance its dual-drive strategy focusing on remote operation and artificial intelligence.